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BACKGROUND: Little is known regarding cancer risks for relatives of women with very early-onset breast cancer.
METHODS:We studied 2208 parents and siblings of 504 unselected population-based Caucasian women with breast cancer diagnosed
before age 35 years (103 from USA, 124 from Canada and 277 from Australia), 41 known to carry a mutation (24 in BRCA1,
16 in BRCA2 and one in both genes). Cancer-specific standardised incidence ratios (SIRs) were estimated by comparing the number
of affected relatives (50% verified overall) with that expected based on incidences specific for country, sex, age and year of birth.
RESULTS:For relatives of carriers, the female breast cancer SIRs were 13.13 (95% CI 6.57–26.26) and 12.52 (5.21–30.07) for BRCA1
and BRCA2, respectively. The ovarian cancer SIR was 12.38 (3.1–49.51) for BRCA1 and the prostate cancer SIR was 18.55
(4.64–74.17) for BRCA2. For relatives of non-carriers, the SIRs for female breast, prostate, lung, brain and urinary cancers were 4.03
(2.91–5.93), 5.25 (2.50–11.01), 7.73 (4.74–12.62), 5.19 (2.33–11.54) and 4.35 (1.81–10.46), respectively. For non-carriers, the SIRs
remained elevated and were statistically significant for breast and prostate cancer when based on verified cancers.
CONCLUSION: First-degree relatives of women with very early-onset breast cancer are at increased risk of cancers not explained by
BRCA1 and BRCA2 mutations.
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Familial aggregation of disease on a population basis is measured
by the increase in risk for closely related relatives of an affected
person. Having one or more close relatives with breast cancer is an
important and well-established risk factor for that disease, and
the magnitude of risk varies depending on the number of, and
relationship to, affected relatives and the ages at which the relatives
were diagnosed. A meta-analysis (Pharoah et al, 1997) and a large
pooled analysis (Collaborative Group on Hormonal Factors in
Breast Cancer, 2001) found that, on average, women have a two-
fold increased risk if they have a first-degree relative with breast
cancer, a three-fold increased risk if they have two affected first-
degree relatives and a four-fold increased risk if they have three
affected first-degree relatives. These increased risks are most
pronounced for younger women and women with at least one
affected relative diagnosed at an early age.
As these studies have generally studied breast cancer across all
ages, little is known regarding the breast cancer risks for relatives
of women with very early-onset breast cancer, such as those
diagnosed before the age of 35 years, let alone their risks of
other cancers except ovarian cancer (Anderson et al, 2000;
Dong and Hemminki, 2001; Hemminki and Granstrom, 2004).
There is no consistent evidence for an increased risk of cancer
at other specific sites, although some studies found a risk of
cancer other than breast cancer (Goldgar et al, 1994; Anderson
et al, 2000).
We have expanded previous work from an Australian study
(Dite et al, 2003) by incorporating data from two further studies
carried out in North America. We used data from the Breast
Cancer Family Registry (Breast CFR), a large international consor-
tium that has enrolled more than 13000 breast cancer families
(John et al, 2004), to study cancer risks for close relatives of
women (index cases) who had very early-onset breast cancer and
had been identified through population-based cancer registries, a
large proportion of whom had been screened for mutations in
BRCA1 and BRCA2. We estimated risks of breast and other cancers
for groups of relatives defined by the BRCA1 and/or BRCA2
mutation status of their index case.
MATERIALS AND METHODS
Subjects
Index cases were women with breast cancer ascertained through
population-based cancer registries and recruited to the Breast CFR in
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(Australia) (McCredie et al, 1998; John et al,2 0 0 4 ) ;s e ea l s ot h e
Supplementary Material. Index cases were restricted to those
diagnosed before the age of 35 years with an incident, first primary
breast cancer who self-reported being Caucasian and for whom
information on their biological parents and full siblings was available.
In San Francisco, 185 (61%) of 301 index cases participated (24
were deceased, 6 had physician-reported contraindications for
contact, 1 was too ill, 20 could not be located, 53 declined to
participate and 8 did not respond). In Ontario, 226 (62%) of 362
index cases participated (for 19 the treating physician refused
permission to contact, for 7 the treating physician could not be
located, 4 were deceased, 11 could not be contacted, 30 refused and
65 did not respond). In Melbourne and Sydney, a breakdown of
participation for cases diagnosed before age 35 years was not
available, but for the 1208 identified index cases under the age of
40 years at diagnosis, 856 (71%) participated (for 102 the treating
physician refused permission to contact, for 10 the treating
physician did not respond, 19 were deceased, 35 had moved, 168
declined to participate and 18 did not respond).
After restricting index cases to those who self-identified as
Caucasian and for whom there was cancer history information on
their biological parents and siblings, a total of 504 index cases (103
from San Francisco, 124 from Ontario, and 277 from Melbourne
and Sydney) were included in this study.
Family cancer histories
All index cases completed the same Breast CFR family history
questionnaire (John et al, 2004) that included an enumeration of at
least all first-degree relatives and information on known cancer
histories. Recruitment of living parents and adult siblings of the index
cases was sought wherever possible. Participating relatives then
provided cancer history information regarding themselves and their
relatives. A substantial proportion of the information collected for
first-degree relatives was provided independently by the relatives
themselves. Documented verification of reported cancers (through
pathology reports, cancer registries and medical records) was sought
wherever possible. Overall, 50% of reported cancers were verified,
63% of breast cancers and 43% of non-breast cancers. Non-
melanoma skin cancers were excluded from analyses. All participants
provided written informed consent before participation and all
studies were approved by the relevant local ethics committees.
Imputation of missing family data
For each index case, the data required on each of their parents and
siblings for these analyses were: relationship to the index case, date
of birth, vital status, age at interview or death, and for those who
had had cancer, the site and age at diagnosis. For some relatives,
one or more of the above data items were missing and could not be
calculated directly from known data. A total of 48 relatives had
missing date of birth, 3 deceased relatives had missing age at death
and 13 with cancer had missing age at diagnosis. In these
instances, data were imputed iteratively using a variation of a
previously developed protocol (Dite et al, 2003); see Supplemen-
tary Material for more details. A further 10 had missing vital status
and were censored at age 20.
BRCA1 and BRCA2 mutation testing
For the purpose of this study, mutations were protein-truncating
or missense mutations classified deleterious as by the Breast
Cancer Information Core (National Human Genome Research
Institute, 2002). Details of testing are given in the Supplementary
Material. BRCA1 and BRCA2 mutation testing was conducted for
84% and 82%, respectively, of all index cases, and of all index cases
with a first-degree family history of breast cancer.
To estimate the number of index case mutation carriers not
identified by testing, we multiplied the number tested by each
method by 1 – proportion of the coding region of the gene covered
(0.9 for sequencing, two-dimensional gel electrophoresis and
heteroduplex; 0.8 for whole gene PTT; 0.6 for limited gene PTT;
and 0.1 for founder mutation screening) and multiplied by the
mutation frequency (0.15 and 0.05 for those with and without an
affected first-degree relative, respectively). For index cases for
whom no testing was conducted, the number of missed mutations
was estimated by multiplying the number not tested by the
mutation frequency above.
Of the 374 tested index cases for whom no mutation was found,
we estimated that 4.7 BRCA1 and 7.3 BRCA2 carriers were not
detected. Of the 89 index cases not tested, we estimated there were
5.3 BRCA1 and 5.6 BRCA2 carriers not detected. Therefore, we
estimated that 5% of the index cases not tested, or found not to
carry a mutation, were carriers.
Cancer incidence
For each cancer site, population-based cancer incidence rates
specific for age (in 5-year groupings), year of birth (in 5-year
groupings), gender and country were obtained for: 1925–1985 in
Connecticut, USA (http://seer.cancer.gov); for 1965–2001 in
Ontario, Canada (Ontario Cancer Registry, 2004); and for
1983–2001 in Australia (http://www.aihw.gov.au). For Ontario
and Australia, cancer incidences were not available before 1965
and 1983, respectively. These incidences were extrapolated from
the available data by calculating the known Ontario and Australian
incidences as a proportion of the Connecticut rates and applying
this proportion to the Connecticut data for the missing years.
Specific cancer sites chosen for inclusion in this study were those
which are known to be common (colorectal, brain, cervix, lung,
stomach, urinary) and/or of particular interest in relation to breast
cancer (ovary, prostate). Urinary cancers were defined as cancers
of the kidney, bladder, ureter and renal pelvis.
Statistical methods
We estimated the standardised incidence ratio (SIR) by comparing
the observed number of affected in a group of relatives to those
expected in the general population. The age-specific cumulative
cancer incidence was estimated by Kaplan–Meier product-limit
survival functions in which failure time was age at cancer
diagnosis. Unaffected relatives were censored at age at completion
of family history questionnaire if alive, age at death if deceased or
age 20 years if vital status was unknown. Cumulative incidence was
defined as the complement of the Kaplan–Meier survival function.
All statistical analyses were performed with STATA version 9,
(2005) (Stata Corporation, College Station, TX, USA). All statistical
tests were two-sided and, following convention, P-values o0.05
were considered nominally statistically significant.
RESULTS
Table 1 shows the centre-specific distribution of the index cases by
age at diagnosis, family history of breast cancer and BRCA1 and
BRCA2 mutation status. The mean age at diagnosis of the index
cases was 31.3 years (s.d. 2.8 years). Of these, 41 carried a mutation
(24 in BRCA1, 16 in BRCA2 and 1 in both genes).
The 504 index cases reported having 504 fathers, 504 mothers,
602 full brothers and 598 full sisters with a combined total of
99648 person-years of observation. The mean (s.d.) person-years
was 59.8 (9.4) for fathers, 58.1 (8.5) for mothers, 33.5 (8.1) for
brothers and 33.6 (7.4) for sisters.
Table 2 shows that the SIRs for breast cancer were elevated
overall and in each of the subgroups defined by relationship to the
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relatives of index cases with mutations in BRCA1 were 3.3 times
that for relatives of index cases who tested negative (P¼0.003) and
2.5 times that for relatives of index cases who were not tested
(P¼0.05). For relatives of index cases with mutations in BRCA2,
the SIR was 3.1 times that for relatives who tested negative
(P¼0.02) and 2.4 times that for relatives who were not tested
(P¼0.1).
Overall, the breast cancer SIR was 1.7 times greater for sisters
than mothers (P¼0.1). For relatives of the index cases not found
to carry mutations in BRCA1 and BRCA2, the SIR was 1.3 times
greater for sisters than mothers (P¼0.5). Although the SIRs for
sisters and mothers were 30 and 15% lower, respectively, for the
relatives of the index cases who were not found to carry a mutation
compared with all index cases, they were both elevated compared
with the general population; see Figure 1.
When analyses were restricted to the 36 verified breast cancers,
the SIR for mothers and sisters was 3.04 (95% CI 2.20–4.20)
overall. For relatives of the index cases found to carry mutations in
BRCA1 and BRCA2, the SIRs were 8.21 (95% CI 3.42–19.72) and
7.51 (95% CI 2.42–23.29), respectively, whereas for relatives of
index cases who were not found to be a carrier or had not been
tested, the SIRs were 2.58 (95% CI 1.71–3.88) and 2.62 (95% CI
1.09–6.28), respectively.
Table 3 shows that the SIRs for all non-breast cancers (excluding
non-melanoma skin cancer) were elevated both overall and for
each of the subgroups, for brothers, the subgroup with the least
observed cancers, the SIR was only marginally elevated. The SIR
for cancers other than breast cancer for fathers and brothers
combined was not different to that for mothers and sisters
combined (P¼0.5). The SIR for brothers and sisters combined was
1.6 times that for fathers and mothers combined (P¼0.03). For the
male relatives, the SIR for fathers was not different to that for
brothers (P¼0.9), whereas for female relatives the SIR for sisters
was 2.5 times that for mothers (Po0.01).
For subgroups defined by mutation status of the index case, the
non-breast cancers SIR for relatives of the index cases who carried
BRCA1 mutations was marginally elevated while the SIR for
relatives of the index cases who carried BRCA2 mutations was not
elevated. Elevated SIRs were seen for relatives of index cases who
had been tested and found not to be a carrier or were untested.
After limiting analyses to relatives of the index cases not found to
carry mutations, the SIRs remained elevated for all subgroups
except for brothers and marginally so for mothers. The SIR for
brothers and sisters combined was higher than for fathers and
mothers combined (P¼0.03) and the SIR for sisters remained
higher than that for mothers (Po0.01).
Table 4 shows cancer site-specific SIRs. The ovarian cancer SIR
was elevated overall (2.46; 95% CI 1.23–4.92; P¼0.01) and for
mothers and sisters of BRCA1 mutation carriers (Po0.001), but
not for mothers and sisters of index cases who tested negative or
were not tested; see also Figure 2. No ovarian cancers were
observed in relatives of BRCA2 mutation carriers.
For prostate cancer, the SIR was substantially elevated overall
(6.54; 95% CI 3.71–11.51; Po0.001) and within subgroups defined
by BRCA2 mutation carrier and testing status (all Po0.001). No
prostate cancers were observed in relatives of BRCA1 mutation
carriers. Using the eight verified prostate cancers only, the SIRs for
fathers and brothers remained elevated and were 4.36 (95% CI
2.18–8.72) overall and 3.75 (95% CI 1.56–9.01) for relatives of
known non-carriers (both Po0.001).
For brain cancer, the SIR was elevated overall (2.79; 85% CI
1.26–6.22; P¼0.01) and for the subset of relatives of known non-
carriers (both P¼0.01). No relatives of known BRCA1 or BRCA2
carriers were diagnosed with brain cancer. When analyses were
restricted to using the four verified brain cancers, the SIRs for
relatives of known non-carriers of 1.86 (95% CI 0.70–4.96) overall
and 2.34 (95% CI 0.88–6.24) were greater than unity but not
significant.
Table 1 Characteristics of index cases
San Francisco Ontario
Melbourne
and Sydney Total
N (%) N (%) N (%) N (%)
Age at diagnosis
20–24 years 5 (5%) 1 (1%) 10 (4%) 16 (3%)
25–29 years 13 (13%) 23 (19%) 57 (21%) 93 (18%)
30–34 years 85 (83%) 100 (81%) 210 (76%) 395 (78%)
Breast cancer family history
a
None 88 (85%) 107 (86%) 252 (91%) 447 (89%)
One 15 (15%) 15 (12%) 21 (8%) 51 (10%)
Two or more 0 (0%) 2 (2%) 4 (1%) 6 (1%)
BRCA1 mutation testing
Not tested 21 (20%) 37 (30%) 27 (11%) 85 (17%)
Negative 74 (72%) 81 (65%) 239 (85%) 394 (78%)
Positive 8 (8%) 6 (5%) 11 (4%)
b 25 (5%)
b
BRCA2 mutation testing
Not tested 24 (23%) 37 (30%) 29 (10%) 90 (18%)
Negative 77 (75%) 80 (65%) 240 (87%) 397 (79%)
Positive 2 (2%) 7 (6%) 8 (3%)
b 17 (3%)
b
aIn mothers or sisters of the index case.
bOne index case had mutations in both
BRCA1 and BRCA2.
Table 2 Risk of breast cancer for mothers and sisters of index cases
Observed Expected SIR (95% CI)
Mothers and sisters combined 59 11.83 4.99 (3.86–6.44)
Mothers 48 10.41 4.61 (3.48–6.12)
Sisters 11 1.42 7.73 (4.28–14.00)
San Francisco 15 3.15 4.77 (2.88–7.91)
Ontario 17 2.86 5.95 (3.70–9.58)
Melbourne and Sydney 27 5.83 4.63 (3.18–6.75)
Mothers and sisters of BRCA1-positive index cases 8 0.61 13.13 (6.57–26.26)
Mothers and sisters of BRCA2-positive index cases 5 0.40 12.52 (5.21–30.07)
Mothers and sisters of BRCA1- and BRCA2-negative index cases 36 8.92 4.03 (2.91–5.93)
Mothers and sisters of BRCA1 and BRCA2 untested index cases 10 1.91 5.23 (2.81–9.72)
Mothers of BRCA1- and BRCA2-negative index cases 30 7.77 3.86 (2.70–5.23)
Sisters of BRCA1- and BRCA2-negative index cases 6 1.16 5.19 (2.33–11.54)
Abbreviations: CI¼confidence interval; SIR¼standardised incidence ratio.
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4.54–10.91; Po0.001) and for relatives of index cases who were
not tested or known not to be carriers (P¼0.05 and Po0.001,
respectively), and for the latter group the SIRs of 5.22 (95% CI
2.72–10.03) for males and 20.34 (95% CI 9.70–42.66) for females
were different (P¼0.007). The SIRs for relatives of BRCA1 and
BRCA2 carriers were not elevated. When restricted to the seven
verified lung cancers, the SIR was elevated overall (SIR¼2.46;
95% CI 1.17–5.17; P¼0.02), and for males (SIR¼2.52; 95%
CI 1.13–5.62); P¼0.02).
For urinary cancers, the SIR was elevated overall (4.45; 95% CI
2.12–9.34; Po0.001) and for relatives of known non-carriers
(P¼0.001). No urinary cancers were observed in the relatives of
BRCA1 or BRCA2 mutation carriers. When analyses were
restricted to using the five verified cancers, the SIR was 3.18
(95% CI 1.32–7.46) overall.
For colorectal cancer, the overall SIR was 0.85 (95% CI
0.48–1.50) while for stomach cancer, the overall SIR was 1.10
(95% CI 0.57–2.11)
DISCUSSION
Mothers and sisters of women with breast cancer diagnosed before
the age of 35 years were at a substantially increased risk of breast
cancer, by a factor that remained high even for those whose index
cases had been tested and found not to carry mutations in BRCA1
and BRCA2. The risk for sisters was greater than for mothers,
consistent with previous studies (Pharoah et al, 1997; Collaborative
Group on Hormonal Factors in Breast Cancer, 2001; Dite et al,
2003). Also consistent with studies of relatives of women with
breast cancer at older ages (Goldgar et al, 1994; Anderson et al,
2000), we found that the parents and siblings were at a 1.5- to
2-fold increased risk of cancers other than breast cancer. The
magnitude of this increased risk was little changed when restricted
to relatives of the index cases who were tested and found not to
carry mutations in BRCA1 and BRCA2.
Overall, first-degree relatives were at increased risks for cancer
of the ovary, prostate, lung, brain and urinary tract. The increased
risk of ovarian cancer was evident only for the relatives of known
BRCA1 mutation carriers, and the increased risk of prostate cancer
was evident only for the relatives of known BRCA2 mutation
carriers. Although based on small numbers, both these observa-
tions are consistent with the literature (Antoniou et al, 2003;
Willems et al, 2008). The increased risks of prostate, brain and
urinary cancers for the relatives of known non-carriers could
therefore represent real and novel associations.
A potential limitation of all studies of familial risk is the
accuracy of data on outcomes for relatives. When comparing with
population data, under-reporting of cancers in relatives (false
BRCA1 and BRCA2 mutation carriers excluded
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Figure 1 Cumulative risk of breast cancer for mothers and sisters
combined.
Table 3 Risk of non-breast cancer for parents and siblings of index cases
a
Observed Expected SIR (95% CI)
Parents and siblings 143 72.44 1.97 (1.68–2.33)
Fathers and brothers 79 38.15 2.07 (1.66–2.58)
Mothers and sisters 64 34.29 1.87 (1.46–2.38)
Parents 114 62.34 1.83 (1.52–2.20)
Siblings 29 10.10 2.87 (2.00–4.13)
Fathers 69 33.05 2.09 (1.65–2.64)
Mothers 45 29.30 1.54 (1.15–2.06)
Brothers 10 5.11 1.96 (1.05–3.64)
Sisters 19 4.99 3.80 (2.43–5.96)
San Francisco 41 16.49 2.49 (1.83–3.38)
Ontario 33 17.10 1.93 (1.37–2.72)
Melbourne and Sydney 69 38.86 1.78 (1.40–2.25)
Index case: BRCA1 positive 8 3.94 2.03 (1.02–4.06)
Index case: BRCA2 positive 5 2.75 1.82 (0.76–4.36)
Index case: negative 107 54.46 1.97 (1.63–2.38)
Index case: untested 23 11.40 2.02 (1.34–3.04)
Index case: negative – fathers and brothers 58 28.40 2.04 (1.58–2.64)
Index case: negative – mothers and sisters 49 22.06 1.88 (1.42–2.49)
Index case: negative – parents 83 46.33 1.79 (1.45–2.22)
Index case: negative – siblings 24 8.13 2.95 (1.98–4.41)
Index case: negative – fathers 50 24.34 2.05 (1.56–2.71)
Index case: negative – mothers 33 21.99 1.50 (1.07–2.11)
Index case: negative – brothers 8 4.06 1.97 (0.98–3.94)
Index case: negative – sisters 16 4.07 3.93 (2.41–6.42)
Abbreviations: CI¼confidence interval; SIR¼standardised incidence ratio.
aExcludes non-melanoma skin cancer.
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cancers in relatives (false positives) inflates risk estimates.
A particular strength of the Breast CFR data was the attempt to
recruit family members of index cases, with the consequence that
the cancer histories of relatives were frequently self-reported or
reported by one or more close relatives. By limiting our analyses to
first-degree relatives of the index case, any cancer histories that
were not self-reported must have been provided by a first-degree
relative. Validation studies have shown that, for self-reports, 91%
of breast cancers and 79% of cancers at other sites are true
positives (Bergman et al, 1998) and that for reports by first-degree
relatives, 88% of breast cancers and at least 70% of cancers at other
sites are true positives (Ziogas and Anton-Culver, 2003) and for all
cancers 99% of negative reports were true negatives (Ziogas and
Anton-Culver, 2003).
In this study, considerable effort was also made to check the
accuracy of the cancer history data and therefore maximise the
validity of the results. Wherever possible, reported family cancers
were validated using cancer registry data, medical reports and
death certificates (John et al, 2004).
For the observed cancers in first-degree relatives (see Table 4),
4 of the 8 ovarian cancers, 8 of the 12 prostate cancers, 4 of the
6 brain cancers, 4 of the 6 urinary cancers and 8 of the 20 lung
cancers had been confirmed by pathology reports, medical records
or death certificates. When analyses were restricted to only using
these verified cancers, the SIRs for relatives of known non-carriers
remained significantly elevated for prostate cancer, and for lung
cancer for subgroups including males (for which the possibility
that the lung cancers could be metastasised breast cancers can be
ruled out), and were numerically greater than unity for the other
cancer groups.
Despite these efforts to collect high-quality data, a potential
weakness of our study remains in that there could be over-
reporting of cancers in case families. In our overall analyses, some
of the non-verified cancers may have been incorrectly reported
while in our analyses of verified cancers only, some of the correctly
reported but not verified cancers have been excluded. The
estimates of SIR from the overall and verified analyses therefore
provide upper and lower limits between which the best estimate of
the true SIR lies.
We limited index cases to Caucasian women to provide a racially
homogeneous (and therefore less genetically heterogeneous) group
of families, and obtained relevant population cancer incidence data
by using historical cancer registry information so that we could
take into account changing cancer-specific incidences over time. In
this regard the dotted lines in Figures 1 and 2 are only an
indication of the risk for the comparison group. The SIR analyses
presented in Tables 2–4 represent the ratio of risks adjusted
analytically for the fact that the cancer risks for relatives depend on
when and where they were living.
A potential weakness of the study is that, although the detection
of mutations in BRCA1 and BRCA2 was comprehensive, it was not
exhaustive and there is a possibility that some mutations in index
cases were missed. There was no systematic difference between
those who were tested and were not tested based on family history
of breast cancer. We estimated that, at most, we may have tested
and misclassified as non-carriers 12 actual mutation carriers
(4.7 in BRCA1 and 7.3 in BRCA2), about 3%. If this was the case
Table 4 Risk of specific cancers for parents and siblings of index cases
Observed Expected SIR (95% CI)
Ovarian cancer (mothers and sisters)
Index case: BRCA1 positive 2 0.16 12.38 (3.10–49.51)
Index case: BRCA2 positive 0 0.11 —
Index case: negative 5 2.45 2.04 (0.85–4.91)
Index case: unknown 1 0.54 1.87 (0.26–13.26)
Prostate cancer (fathers and brothers)
Index case: BRCA1 positive 0 0.13 —
Index case: BRCA2 positive 2 0.11 18.55 (4.64–74.17)
Index case: negative 7 1.33 5.25 (2.50–11.01)
Index case: unknown 3 0.26 11.51 (3.71–35.69)
Colorectal cancer (parents and siblings)
Index case: BRCA1 positive 1 0.74 1.35 (0.19–9.57)
Index case: BRCA2 positive 1 0.49 2.03 (0.29–14.41)
Index case: negative 8 10.77 0.74 (0.37–1.49)
Index case: unknown 2 2.09 0.96 (0.24–3.83)
Brain cancer (parents and siblings)
Index case: BRCA1 positive 0 0.11 —
Index case: BRCA2 positive 0 0.07 —
Index case: negative 5 1.61 3.10 (1.29–7.45)
Index case: unknown 1 0.36 2.76 (0.39–19.60)
Cervical cancer (mothers and sisters)
Index case: BRCA1 positive 0 0.40 —
Index case: BRCA2 positive 0 0.30 —
Index case: negative 9 6.18 1.46 (0.76–2.80)
Index case: unknown 0 1.32 —
Lung cancer (parents and siblings)
Index case: BRCA1 positive 1 0.17 5.95 (0.84–42.21)
Index case: BRCA2 positive 1 0.11 9.18 (1.29–65.20)
Index case: negative 16 2.07 7.73 (4.74–12.62)
Index case: unknown 2 0.50 4.00 (1.00–16.00)
Stomach cancer (parents and siblings)
Index case: BRCA1 positive 0 0.60 —
Index case: BRCA2 positive 0 0.45 —
Index case: negative 8 7.77 1.03 (0.52–2.00)
Index case: unknown 0 1.61
Urinary cancers (parents and siblings)
Index case: BRCA1 positive 0 0.09 —
Index case: BRCA2 positive 0 0.06 —
Index case: negative 5 1.15 4.35 (1.81–10.46)
Index case: unknown 2 0.28 7.23 (1.81–28.90)
Abbreviations: CI¼confidence interval; SIR¼standardised incidence ratio.
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Figure 2 Cumulative risk of ovarian cancer for mothers and sisters
combined.
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would predict that we have slightly over-estimated the true breast
cancer risk for relatives of non-carriers. This is unlikely to explain
the increased cancer risks seen in the restricted analyses.
Our results provide evidence for the existence of familial factors,
such as variants in genes other than BRCA1 and BRCA2, which
contribute to the increased risks for breast, prostate, lung and/or
brain cancers in relatives of women with very early-onset breast
cancer. This has implications for gene discovery by focussing
attention on families known not to be segregating BRCA1 or
BRCA2 mutations with one or more breast cancers diagnosed at a
young age as well as one or more of the above cancers. This
approach would be similar to those that had pivotal roles in
localising BRCA1 through using breast–ovary cancer families
(Easton et al, 1993), and cloning BRCA2 through studying breast
cancer families with male breast cancer (Wooster et al, 1995).
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